Past Events

Cambridge Healthtech Institute is pleased to present its Ninth Annual PEGS, the essential protein engineering summit, being held this April 29-May 3, 2013 at the Seaport World Trade Center in Boston. In addition to a new venue, the 2013 PEGS event offers six streams in the areas of protein & antibody engineering, oncology, expression, analytical, safety, and purification. These highly-focused streams enable researchers to discuss and find solutions to challenges faced in the lab and hear research that has yet to be published. Conference short courses offer a primer or in-depth workshop on everything from phage and yeast display to immunogenicity and protein therapeutics. A biologics partnering forum will also be offered for both emerging companies with innovative technologies and established companies seeking collaborations. Year after year, PEGS challenges attendees to evolve their thinking about the generation, characterization, and clinical application of proteins. Join over 1,200 of your colleagues this April in Boston to make your mark on the rapidly changing landscape of protein and antibody engineering.

The complexity of APIs and fine chemicals has been increasing over the years and more and more stringent purity targets have to be met to comply with ever tougher regulations. At the same time, the economic pressure continuously drives down the costs of production. The combination of complexity and purity represents a real challenge for the pharmaceutical and fine chemical manufacturing industry, and traditional synthetic methods often become a bottleneck. This new conference will illustrate how novel approaches combining smart multi-step synthesis pathways combined with advanced purification technologies can deliver the desired high quality product at both development and production scale, in a time-efficient and cost-effective manner. Presented by experts from several innovating pharmaceutical, agrochemical and fine chemical companies, a number of development and industrial case studies will be presented thereby highlighting how these novel strategies can meet the industry's evolving challenges.

Drug Discovery Chemistry is the leading discovery event in medicinal chemistry. Focused on novel small molecules as therapeutic targets, with a strong emphasis on a chemistry-based approach, this unique event brings together top experts from the pharmaceutical industry, academia, and government organizations, and consists of the following six conferences: - 4th Anti-Inflammatories: Small Molecule Approaches - 8th Fragment-Based Drug Discovery: From Discovery to Lessons Learned - Inaugural Constrained Peptides and Macrocyclics Drug Discovery: Novel Peptide Therapeutics - 4th Kinase Inhibitor Chemistry: Charting the Chemical Space - 6th Protein-Protein Interactions: Targeting PPI for Therapeutic Interventions - Inaugural GPCR-Based Drug Design: Computational and Structural Approaches New for this year is a special Plenary Keynote presentation on April 16 by Nobel Laureate Dr. Jack Szostak who will discuss mRNA display - from basic principles to macrocycle drug discovery.

Advances in microfluidics and nanofabrication have led to the manufacture of technologies capable of utilizing hundreds to millions of small-scale partitions. Digital enumeration, whether it is done through digital PCR, microfluidics, or next-generation sequencing, is finding growing utility in both basic research and clinical applications. By allowing for detection of nucleic acids at higher resolution and lower target levels, digital detection technologies have the ability to identify diseases earlier in progression, providing an advantage for diagnostics and preventative medicine. Cambridge Healthtech Institute's Inaugural Integrating Digital PCR conference will cover digital PCR, microfluidics, and single-cell analysis and how these technologies are best used in a clinical setting. The evolution of qPCR to a more digital format, as well as the role that next-generation sequencing will play, will also be discussed. Special focus will be given to clinical translation and future trends driving the field.

Pattern recognition receptors (PRRs), such as toll-like receptors (TLRs) and NOD-like receptors, play an important role in recognizing PAMPs and DAMPs (peptides released as inflammatory response), which makes them key effectors of immunity and excellent anti-inflammatory targets for pharmaceutical drug development. This conference highlights novel developments and emerging opportunities in targeting pattern recognition receptors for health and disease. Coverage will include the therapeutic potential for inflammatory diseases and developing opportunities for infectious diseases and cancer.

Pre-detection processing is a pivotal part of molecular diagnostics. Its modernization should closely follow or even precede the emergence of new diagnostic technologies. Cambridge Healthtech Institute's Sample Prep and Target Enrichment in Molecular Diagnostics is designed to demonstrate the latest advances in pre-analytical processing, sample preparation and target enrichment in molecular diagnostics and particularly in nucleic acid testing. IVD industry scientists and academia researchers who are working in this exciting area should attend this meeting.

ARROWHEAD'S 2nd Annual Cancer Immunotherapy Conference will provide a comprehensive review of cutting edge research and development in two areas: Cancer Stem Cells as a new category of Targets for Immune Intervention for solid and hematological malignancies Hematopoietic Stem Cell and T Cell Engineering for cancer immunotherapy The conference is bringing together leading scientists and C-Level executives from across the globe to present research, case studies and viewpoints on topics related to stem cells and cancer immunotherapy.

Next-Generation Sequencing (NGS), along with a shift toward personalized medicine, is poised to revolutionize the drug discovery paradigm by offering unprecedented interrogation of the human genome at high resolution, and relatively low costs. While the widespread implementation of NGS is apparent, issues specific to drug development present new challenges for developers, including discerning actionable genomic information for novel targets, markers and utilization in clinical trials; developing informatics infrastructure and pipelines to deal with the computational complexity of NGS data; and navigating regulatory hurdles of informed consent and data sharing. Cambridge Healthtech Institute is proud to announce the Inaugural NGS for Drugs, Patients and Clinical Trials, designed with drug developers in mind, to explore the unparalleled advantages of NGS technologies for translational research, while addressing common challenges.

NGS has enabled faster and cheaper mapping of DNA/RNA, allowing genomic comparisons and accelerating genomic discoveries. Cambridge Healthtech Institute is proud to host the Fourth Annual X-Gen Congress and Expo, which is uniquely designed to cover these technological advances and discover advancing applications. With the focus now on clinical utility, find out why data analysis is the driving force that enables discovery, and is sequencing’s strategic step.

CHI's Fourth Annual Biotherapeutics Analytical Summit will be taking place March 11-14, 2013 in Baltimore, Maryland. This event features 150+ industry, regulatory and biosimilar professionals gaining insight into analytical characterization and comparability for change implementation through case studies, interactive break-out discussions, networking opportunities and more!

At Organic Process Research & Development Conference, you will hear detailed presentations and case studies from top international chemists. Our hand-picked programme of speakers has been put together specifically for an industrial audience. They will discuss the latest issues relating to synthetic route design, development and optimisation in the pharmaceutical, fine chemical and allied fields.

The 3rd Annual Traumatic Brain Injury Conference is bringing researchers, clinicians in industry, academia and the military, and regulators together to discuss how best to achieve the goal of bringing new therapies to market for TBI. In order to do so, there is a strong need for consensus regarding key subject areas, which will be covered in depth via plenary sessions and panel sessions at this year's conference.

microRNAs are playing an important role in a range of diseases such as cancer, metabolic diseases and cardiovascular disorders. Their involvement in many physiological pathways makes them an excellent target for pharmaceutical drug development, and their use as biomarkers or for profiling and screening turns them into a valuable tool for diagnostics. This conference highlights novel developments in using miRNAs for health and disease, and it will discuss novel applications and progress made in manipulating microRNA. Opportunities for using microRNA as a tool will also be explored.

The 20th International Molecular Med Tri-Conference is the leading drug discovery research event covering a broad spectrum of cutting-edge topics within molecular medicine with scientific, business and regulatory viewpoints. Join over 3,000 of your colleagues in interactive lectures, discussions, and various networking receptions to hear differing views and perspectives on poignant issues facing you and our industry today. Spanning five days, the Tri-Conference includes 5 Concurrent Symposia, the Emerging Molecular Diagnostics Partnering Forum, 15 Afternoon & Dinner Short Courses and 15 Conference Programs. -Bioinformatics in the Genome Era -Integrated R&D Informatics and Knowledge Management -Molecular Diagnostics -Mastering Medicinal Chemistry -Personalized Diagnostics -Cancer Molecular Markers -Circulating Tumor Cells -Digital Pathology -Cell Therapy -Cancer Biologics -Clinical and Translational Science -Clinical Sequencing -Cancer Molecular Markers -Predictive Pre-clinical Models in Oncology -Oncology Clinical Trials

The Summit for Clinical Trials Operations Executives (SCOPE): Overcoming Key Challenges in Forecasting, Site Selection, Recruitment, Data Collection and Project Management is taking place February 5-7, 2013 in Miami, FL. The program will offer eight conferences and six pre-conference short courses. Each conference will feature best practice case studies relevant to clinical operations experts and those new to the field.

CHI's PepTalk: The Protein Science Week is more than just a conference. It is a community dedicated to the evolving field of biotherapeutics and a gateway to the future of biologics. The continuous growth and success of PepTalk is due to the commitment and quality of scientific programming. Join us January 21-25 in Palm Springs, California to learn about the advances and debate the challenges in protein-based therapeutics.

This prestigious event has an impressive line-up of academic and industrial speakers who will present the latest innovations in bioorganic and medicinal chemistry.

We are pleased to announce XX International Conference on Chemical Reactors "CHEMREACTOR-20" to be held in December 3-7, 2012 in Luxemburg

Although production of new polymorphs and solvates can be a source of profit for companies through extension of the patent lifetime, the inability to manufacture a consistent crystalline form often leads to costly project delays, particularly in chemical development. This conference will focus on these issues from the viewpoint of the process chemist and chemical engineer; i.e. on chemical development issues which impact the ability to routinely manufacture the chosen crystalline form, whether this be the most stable or a metastable crystal. Case studies from different companies will show how different organisations identify and solve these extremely difficult issues in different ways, depending on how far the project is along the development time line. Experts in the field will also give lectures on problem solving and troubleshooting, as well as giving insight into new techniques, (supercritical fluids, polymorph prediction etc.) which will be of value in the future.

Hype or reality? Much has been made of developments in catalysis in synthetic organic chemistry. This Scientific Update event aims to bring together industrial chemists and academics to learn about emerging catalytic methods and their industrial application. Featuring top speakers from academia and industry, this event will provide industrial chemists with an unparalleled opportunity to explore how catalysis is beginning to change the landscape of process chemistry. How will this conference help you? This conference will attract an international audience of around 100-150 delegates and is intended for senior chemists and technical managers from the Pharmaceutical, Fine and Speciality Chemical, Agrochemical, Flavour, Fragrance and Colour Chemical industries. A detailed, high-quality book of conference proceedings covering all the presentations is provided and there will be ample opportunity for questions and stimulating discussion during the conference.